Furthermore, several clinical studies demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) can reduce the risk of dementia in T2DM patients by improving memory and learning and overcoming cognitive impairment [12]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.